Government Caps Trade Margins on Cancer Drugs to 30%
The Indian government has implemented a 30% cap on trade margins for non-scheduled anti-cancer drugs, potentially reducing prices by up to 70%.
The cap on trade margins could save patients approximately Rs 2,500 crore annually.
The Supreme Court's scrutiny of drug pricing led to this significant policy change.
Around 82% of drugs in India are non-scheduled, with many used for cancer treatment.
In a significant move aimed at making cancer treatment more affordable, the Indian government has announced a 30% cap on trade margins for all non-scheduled anti-cancer drugs. This decision is expected to lower the maximum retail prices (MRPs) of these medicines by as much as 70%, potentially saving patients around Rs 2,500 crore each year.
The government's action follows recent scrutiny by the Supreme Court regarding the exorbitant mark-ups in the pricing of cancer medications. The court highlighted the stark contrast between the prices at which these drugs are supplied to retailers and the MRPs charged to patients. This intervention is part of a broader effort to ensure that life-saving treatments remain accessible to those in need.
The cap will apply to both branded and generic medicines, encompassing domestic and imported drugs, whether patented or not. Currently, about 82% of the drugs consumed in India are non-scheduled, with nearly 110 of these specifically used for cancer treatment. The high costs associated with these medications have been a significant financial burden for many families, leading to what is often termed 'financial toxicity'.
The Supreme Court's involvement was prompted by concerns over a particular cancer drug that had a reported supply price of around Rs 2,700 but was sold to patients at an MRP of Rs 27,000, illustrating the need for regulatory intervention. The court had previously suggested a uniform margin for medicines, which the government has now addressed by extending the Trade Margin Rationalisation (TMR) approach to non-scheduled cancer drugs.
While this new policy is a step forward, some patient rights advocates argue that it does not sufficiently address the underlying manufacturing costs and may still allow for high base prices. The government, however, anticipates that this intervention will lead to substantial reductions in MRPs, benefiting patients significantly. The pharmaceutical industry has expressed concerns regarding the balance between affordability and sustainability, emphasizing the need for continued innovation and quality in drug manufacturing.
